Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.51 |
| ▸ | VCP | P55072 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13002992 | 0.86 | MPL (0.49) | MPLNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1765087 | 0.86 | MPL (0.49) | MPLNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8239502 | 0.83 | MPL (0.51) | MPLNPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL19195983 | 0.82 | SCN9A (0.64) | MPLNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL12206495 | 0.81 | RAB9A (0.49) | MPLNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8698425 | 0.81 | ATP4A (0.57) | NPC1RAB9AALDH1A1GAAMAPT | |
| SCHEMBL11961418 | 0.81 | HTR1B (0.44) | MPLNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL19625307 | 0.81 | MPL (0.60) | MPLNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL44739 | 0.79 | MPL (1.00) | MPLNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3775075 | 0.79 | MPL (0.68) | MPLNPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| EP-3394056-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2020002090-A1 | SUBSTITUTED THIAZOLYLPYRROLONES, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-01-02 | — | — | WO | disclosed |
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-11-23 | — | — | US | disclosed |
| WO-2017112777-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
| US-7968577-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20100063051-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-11 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
| WO-1998017631-A2 | SUBSTITUTED OXIME-ETHERS AND THEIR USE AS PESTICIDES | NOVARTIS AG (CH) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063051-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFRKB, NFKB2, NFKBIA | MPL 4448/4885NPC1 1595/4885RAB9A 2635/4885 |
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | MPL 2916/4885NPC1 1078/4885RAB9A 1416/4885 |
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | WNT1, WNT3A, CTNNB1 | MPL 2005/4885NPC1 2489/4885RAB9A 3162/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | MPL 986/4885NPC1 2024/4885RAB9A 2641/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | MPL 986/4885NPC1 2024/4885RAB9A 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.